Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Fevzi Altuntas and Serdal Korkmaz.
Fevzi Altuntas
Connection Strength
3.772
Serdal Korkmaz
  1. Hematopoietic progenitor cell mobilization. Transfus Apher Sci. 2017 12; 56(6):787.
    View in: PubMed
    Score: 0.741
  2. What is the role of biosimilar G-CSF agents in hematopoietic stem cell mobilization at present? Transfus Apher Sci. 2017 Dec; 56(6):795-799.
    View in: PubMed
    Score: 0.741
  3. Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients. Transfus Apher Sci. 2021 Dec; 60(6):103237.
    View in: PubMed
    Score: 0.241
  4. Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci. 2021 02; 60(1):103017.
    View in: PubMed
    Score: 0.229
  5. The outcome ofancy. COVID-19 in patients with hematological malign J Med Virol. 2021 03; 93(3):1255.
    View in: PubMed
    Score: 0.228
  6. COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2021 04; 56(4):952-955.
    View in: PubMed
    Score: 0.228
  7. Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci. 2021 Feb; 60(1):102955.
    View in: PubMed
    Score: 0.226
  8. Convalescent plasma therapy in patients with COVID-19. J Clin Apher. 2020 Aug; 35(4):367-373.
    View in: PubMed
    Score: 0.223
  9. Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption. Transfus Apher Sci. 2020 Aug; 59(4):102855.
    View in: PubMed
    Score: 0.222
  10. Current status of art mobilization in Myeloma. Transfus Apher Sci. 2017 Dec; 56(6):850-853.
    View in: PubMed
    Score: 0.186
  11. Management of mobilization failure in 2017. Transfus Apher Sci. 2017 Dec; 56(6):836-844.
    View in: PubMed
    Score: 0.185
  12. COVID-19 clinical course and blood groups: Turkish population-based study Turk J Med Sci. 2021 08 30; 51(4):1659-1664.
    View in: PubMed
    Score: 0.060
  13. Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers. Intern Emerg Med. 2022 01; 17(1):135-139.
    View in: PubMed
    Score: 0.059
  14. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2020 Oct; 26(7):1676-1682.
    View in: PubMed
    Score: 0.056
  15. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021 02; 93(2):1099-1104.
    View in: PubMed
    Score: 0.056
  16. Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy. J Chemother. 2018 Feb; 30(1):44-48.
    View in: PubMed
    Score: 0.046
  17. Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience. Hematol Oncol. 2018 Feb; 36(1):116-120.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.